Machine Learning

A 30-year study reveals massive ice loss, with commercial satellites providing an unprecedented, all-weather view of our planet's changing climate.

Amid a strategic overhaul, Hepion Pharmaceuticals is licensing a novel RNA-based liquid biopsy, aiming to transform early liver cancer detection.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

A new report reveals 87% of firms use AI in customer education, but a dangerous lack of strategy and governance threatens quality, security, and ROI.

A new AI reasoning agent promises to move telcos toward Level 4 autonomy, automating complex network operations and boosting efficiency.

As AI reshapes software, Tricentis is taking its Transform conference global, pushing a new paradigm of 'agentic quality engineering.' Here's what it means.

Former Novo Nordisk CSO Marcus Schindler joins Cradle, validating AI's role in accelerating drug discovery and reshaping traditional pharmaceutical R&D.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

A new report shows fraud fears in private credit are soaring, fueled by AI and bankruptcies, but data reveals a different story for secured lenders.

EyeMD EMR rebrands as Optivate, launching a unified, AI-driven platform. This move signals a new chapter for eye care practice management.

Creality's new Sermoon P1 combines standalone processing and multi-mode lasers, offering industrial-grade 3D scanning at a disruptive price point.

A novel inhaled RNA therapy for a specific group of cystic fibrosis patients gains EMA fast-track status, promising accelerated access to new treatment.

A new trial for a cell therapy targeting a rare eye disease offers hope, driven by a patient-advocate's journey and with potential to treat common AMD.

The soundtracking giant's new desktop app lets creators drag and drop music directly to their timeline, cutting production time and boosting flow.

At ECR 2026, Subtle Medical showcases AI that boosts existing scanners, expands into CT, and promises faster, clearer diagnostics for patients.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

A new partnership combines intelligent routing and a NaaS platform to solve AI's biggest network challenges, targeting the booming Asia-Pacific market.

At QuanCon 2026, Quantexa unveiled a landmark partnership with Moody’s, positioning Decision Intelligence as the core of next-gen AI organizations.

Post-listing, the Swiss HealthTech firm pushes for US market expansion and European reimbursement, streamlining its focus on AI-powered brain health.

A novel CRISPR-based therapy safely targets deadly E. coli in the gut, showing promise in the fight against antibiotic resistance and for protecting cancer patients.